GBT Announces New Employment Inducement Grants
Global Blood Therapeutics (GBT) announced the allocation of restricted stock units (RSUs) to 19 new employees on March 1, 2022, totaling 42,380 shares. These awards were granted as an inducement for joining the company in compliance with NASDAQ Listing Rule 5635(c)(4). The RSUs are part of GBT's Amended and Restated 2017 Inducement Equity Plan, designed to attract talent in the biopharmaceutical sector. GBT focuses on developing treatments for sickle cell disease, including the FDA-approved Oxbryta and an advancing pipeline of therapies.
- Attracting talent through stock unit grants, indicating positive organizational growth.
- Demonstrates commitment to employee retention and motivation.
- None.
SOUTH SAN FRANCISCO, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on March 1, 2022, the compensation committee of GBT’s board of directors granted 19 new employees restricted stock units for an aggregate of 42,380 shares of the company’s common stock. These awards were made under GBT’s Amended and Restated 2017 Inducement Equity Plan (the Plan).
The above-described awards were each granted as an inducement material to the employees entering into employment with the company in accordance with NASDAQ Listing Rule 5635(c)(4), and were granted pursuant to the terms of the Plan. The Plan was adopted by GBT’s board of directors in January 2017 and has been amended and restated from time to time.
About Global Blood Therapeutics
Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments that provide hope to underserved patient communities. Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta® (voxelotor), the first FDA-approved medicine that directly inhibits sickle hemoglobin (HbS) polymerization, the root cause of red blood cell sickling in SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in Phase 3 development to address pain crises associated with the disease, and GBT021601 (GBT601), the company’s next generation HbS polymerization inhibitor. In addition, GBT’s drug discovery teams are working on new targets to develop the next generation of treatments for SCD. To learn more, please visit www.gbt.com and follow the company on Twitter @GBT_news.
Contact:
Steven Immergut (media)
650-410-3258
simmergut@gbt.com
Courtney Roberts (investors)
650-351-7881
croberts@gbt.com
FAQ
What stock units were granted by GBT on March 1, 2022?
Under which plan were the RSUs granted?
What is GBT's focus in the biopharmaceutical sector?
Is GBT's Oxbryta FDA-approved?
What is the significance of the RSU grants?
